We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urine Test for Tuberculosis Needs Improving

By LabMedica International staff writers
Posted on 17 Aug 2011
A noninvasive urinary assay for tuberculosis (TB) is not accurate enough to be used for routine diagnosis of active tuberculosis. More...


The assay works by detecting the heat-stable glycolipid that is present in the cell walls of Mycobacterium tuberculosis and released from active or degrading cells during an infection.

A meta-analysis of and systematic review was conducted on the use of the lipoarabinomannan (LAM) urinary assay for the diagnosis of active TB. Scientists pooled data from nine studies that compared LAM urine testing to an accepted reference, such as positive culture or nucleic acid amplification for TB. Included were trials from Sweden, Ethiopia, Tanzania, Zimbabwe, South Africa, and India, with a total of close to 3,000 people.

In seven studies that only included microbiologically confirmed cases of TB, LAM sensitivity ranged from 13% to 93%, and specificity was 87% to 99%. Sensitivity also varied widely in two additional analyses that counted clinically confirmed cases as either positive or negative for TB. The team stated the assay was more accurate in HIV-positive patients. In that group, its sensitivity for TB was 3% to 53% higher than in HIV-negative individuals, with similar specificity. Sensitivity was highest when immunosuppression was advanced, in which case there might be more LAM in the urine for detection.

Dick Menzies, MD, a lead author of the study from the Montreal Chest Clinic (Montreal, QC, Canada), said, "The LAM urine assay has many characteristics which make it a potentially useful rule-in TB diagnostic, but this review found inadequate sensitivity to use the LAM assay for the diagnosis of TB in unselected cohorts." However, further studies are warranted to evaluate the added value of the LAM assay, known as Clearview TB ELISA (Inverness Medical Innovations; Princeton, NJ, USA) in the diagnosis of active TB. It is especially important for individuals with advanced HIV and in children as well as to assess newer versions of this test with technical advances compared to those in the study. The review was published online on July 4, 2011, in the European Respiratory Journal.

Related Links:

Montreal Chest Clinic
Inverness Medical Innovations



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.